The study, published in the Journal of the American College of Cardiology, followed 565 patients with chronic heart failure due to low ejection fraction across 51 centers. Half the patients received a special immunomodulatory cell-type called mesenchymal precursor cells. The treatment improved the heart’s pumping ability and reduced the risk of heart attack or stroke, especially in patients with high levels of inflammation, researchers said.
This is also the first time MPCs have been used to treat inflammation in heart failure, according to a Feb. 27 Texas Heart Institute news release. Cell therapy could be a synergistic and additive treatment to heart failure medications.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
